Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc. reported a combined revenue increase of 18% year-over-year, totaling $483 million, with management projecting potential peak sales exceeding $1 billion by 2029. The company is actively pursuing growth for its IBSRELA product through ongoing Phase 3 trials for chronic idiopathic constipation, with topline data expected by 2027, while Xphozah's revenue guidance for fiscal year 2026 is set at $110 million to $120 million, bolstered by increasing prescribing patterns. Additionally, a significant 41% growth in the ex-Medicare Xphozah segment in 2025 reflects the effectiveness of Ardelyx's strategic investments in its sales and patient assistance initiatives, which are driving enhanced prescription volumes and patient engagement.

Bears say

Ardelyx Inc is facing significant financial challenges, as indicated by management's expectation of typical seasonal headwinds leading to an anticipated 18% quarter-over-quarter decline in Ibsrela sales for the first quarter of 2026, despite a projected full-year revenue of $422 million. The company's guidance for over $1 billion in peak net sales for Ibsrela appears overly optimistic and not yet reflected in market pricing, compounded by potential adverse effects of changes in reimbursement pricing structures and restrictions on product labeling that could hinder market traction. Additionally, Ardelyx reported a net loss of $0.4 million in the fourth quarter of 2025, alongside concerning adherence rates among patients, which further complicates the prospects for sustaining profitable growth.

Ardelyx (ARDX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ardelyx (ARDX) has a Strong Buy consensus rating as of Mar 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.